EFPIA acknowledges the signature of the EU-New Zealand FTA. The research based pharmaceutical industry notes with disappointment that the final text of the agreement fails to secure improved intellectual property (IP) provisions in New Zealand, a fellow developed, OECD country with one of the weakest IP regimes. We firmly believe that each developed country should play its part in support for innovation for the benefits of all countries.

We remain hopeful that the two sides will establish alternative platforms and dialogues where further discussions can take place to continue the work to bring the two IP regimes to the same level to the benefit of patients, who can then have faster access innovative treatments.